Expert Speaker Faculty

View your esteemed global speaker faculty for the Novel CNS Biomarkers Summit Europe.

Valerie Daggett

Founder & Chief Executive Officer
AltPep
Hakon Hakonarson - Expert Speaker for Novel CNS Biomarkers Summit Europe

Hakon Hakonarson

Founder
Arctic Therapeutics

Nuno Pires

Senior Manager Rare Diseases & Modalities In Vivo Pharmacology and Translation
Bial

Aleksandra Zemla-Brown

Clinical Biomarkers Consultant
Dompé

Wolfgang Liedtke

Global Program Head Neurology
Duke University

Amelie Schreieck

Senior Manager - Biomarker Development
Immunic Therapeutics

Jens Mikkelsen

Professor, University of Copenhagen
Institute of Neuroscience

Jordi Clarimon

Neurological Disorders & Biofluid Specialist
Lundbeck

Kiri Granger

Co-Founder & Chief Scientific Officer
Monument Therapeutics

Lluis Riera-Ponsati

Director - Preclinical Development
Neumirna Therapeutics

Sarah Almond

Vice President - Translational Biology
NRG Therapeutics

Tauseef Butt

President & Chief Executive Officer
Progenra Inc

Joseph Sutton

Biomarker Studies Asset Manager
Roche

Elia Hall

Senior Scientist, Biosample Project Leader
Roche

Isabella Premoli

Director - Translational Medicine
Saniona

Jessica nakhle

Director, Head of Clinical Biomarkers Neuroscience & Immuno-inflammation, Translational Medicine
Servier

Nanh Nguyen

Translational Medicine Biomarker Lead
UCB
Event Image - Novel CNS Biomarkers Summit Europe

Explore the Agenda

Discover the latest case studies and practical strategies shaping the future of CNS biomarker development from Lundbeck, Roche, UCB & more.

View Presentations & Speakers
Event Image - Novel CNS Biomarkers Summit Europe

Partner With Us

Position your brand alongside Europe's leading biomarker innovators and connect with decision-makers actively seeking new technologies and partners.

Explore Sponsorship Options
Event Image - Novel CNS Biomarkers Summit Europe

Join Biopharma Experts

Exchange ideas with biomarker, translational medicine and clinical development leaders tackling the biggest challenges in neurodegenerative drug development.

Register Now